Therapeutic Plasma Exchange: Indications and Outcomes. Single-Center Registry



Abstract Views
1321

Downloads
542

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Dec 21, 2021
Published Feb 1, 2022
10.24018/clinicmed.2022.3.1.163

Abstract viewed = 1321 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

Introduction: Therapeutic plasma exchange is used to manage immune-mediated diseases as early as 1970th. Nevertheless, the evidence beyond the therapeutic indication is still anecdotal and depends on observational data and national registries from different parts of the world. Aim of the Study: To review the use of therapeutic plasma exchange (TPE) to manage different conditions in the Dubai Hospital-nephrology department and benchmark against standard indications categories by American Society of Apheresis (ASFA) guidelines.

Methods: The study included all adult patients who performed TPE in Dubai Hospital during 24 months period from January 2017 until December 2019. Patient demographics, indications, anticoagulation used, the number of sessions, duration of hospitalization, ICU admission, mortality outcome, and occurrence of procedure-related complications were included.

Results: During the 24 months, 142 TPE sessions were performed for 33 registered patients (an average of 4.3 sessions/patient). The most common indications for TPE use in our registry were nephrology-related indications in 119 sessions (85%), while non-nephrology indications contributed for 21 sessions (15%). Among Nephrology related Indications, Thrombotic Thrombocytopenic purpura was the most common indication (47.8%), followed by post kidney transplantation (21%), while non-Nephrology-related indications were mainly for pancreatitis with Hypertriglyceridemia (9.2%). Complications arose in 2 sessions (1.4%), and mortality occurred in one (3%) critically ill patient related to non-procedure consequences and the severity of the underlying disease.

Conclusion: Our registry data confirm the safety of therapeutic plasma exchange in a professional, well-equipped nephrology setting when used for proper evidence-based indications with a lower rate of morbidity and mortality.

Keywords: Albumin, anticoagulation, fresh frozen plasma (FFP), therapeutic plasma exchange (TPE), thrombotic thrombocytopenic purpura (TTP)

References

  1. Kaplan AA, Halley SE. Plasma exchange with a rotating filter. Kidney International. 1990; 38(1): 160-6.
     Google Scholar
  2. Kaplan AA. Therapeutic plasma exchange: a technical and operational review. Journal of Clinical Apheresis. 2013; 28(1): 3-10.
     Google Scholar
  3. Okafor C, Ward DM, Mokrzycki MH, Weinstein R, Clark P, Balogun RA. Introduction and overview of therapeutic apheresis. Journal of Clinical Apheresis. 2010; 25(5): 240-9.
     Google Scholar
  4. Johnson JP, Moore Jr J, Austin HA, Balow TT. Antonovych, and CB Wilson. Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine. 1985; 64: 219-27.
     Google Scholar
  5. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. New England Journal of Medicine. 1992; 326(21): 1373-9.
     Google Scholar
  6. McLeod BC, Wu KK, Knospe WH. Plasmapheresis in thrombotic thrombocytopenic purpura. Archives of Internal Medicine. 1980; 140(8): 1059-60.
     Google Scholar
  7. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. New England Journal of Medicine. 1991; 325(6): 393-7.
     Google Scholar
  8. Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. Journal of the American Society of Nephrology. 2007; 18(3): 886-95.
     Google Scholar
  9. Madore F, Lazarus JM, Brady HR. Therapeutic plasma exchange in renal diseases. Journal of the American Society of Nephrology. 1996; 7(3): 367-86.
     Google Scholar
  10. Matalon A, Markowitz GS, Joseph RE, Cohen DJ, Saal SD, Kaplan B, et al. Plasmapheresis treatment of recurrent FSGS in adult renal transplant recipients. Clinical Nephrology. 2001; 56(4): 271-8.
     Google Scholar
  11. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. American Journal of Kidney Diseases. 1994; 23(6): 817-27.
     Google Scholar
  12. American Medical Association Panel. Current status of therapeutic plasmapheresis and related techniques: report of the AMA panel on therapeutic plasmapheresis. JAMA. 1985; 253: 819-25.
     Google Scholar
  13. Schmidt JJ, Asper F, Einecke G, Eden G, Hafer C, Kielstein JT. Therapeutic plasma exchange in a tertiary care center: 185 patients undergoing 912 treatments-a one-year retrospective analysis. BMC Nephrology. 2018; 19(1): 1-7.
     Google Scholar
  14. Walters G. Role of therapeutic plasmapheresis in ANCA-associated vasculitis. Pediatric Nephrology. 2016; 31(2): 217-25.
     Google Scholar
  15. Korkmaz S, Keklik M, Sivgin S, Yildirim R, Tombak A, Kaya ME, Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura: a retrospective multicenter study. Transfus Apher Sci. 2013; 48(3): 353-8.
     Google Scholar
  16. Prendecki M, Pusey C. Plasma exchange in anti-glomerular basement membrane disease. La Presse Médicale. 2019; 48(11): 328-37.
     Google Scholar
  17. Xie P, Tao M, Peng K, Zhao H, Zhang K, Sheng Y, et al. Plasmapheresis therapy in kidney transplant rejection. Blood Purification. 2019; 47(1-3): 73-84.
     Google Scholar
  18. Padmanabhan A, Connelly‐Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. Journal of Clinical Apheresis. 2019; 34(3): 171-354.
     Google Scholar
  19. Truong AD, Auld SC, Barker NA, Friend S, Wynn AT, Cobb J, et al. Therapeutic plasma exchange for COVID-19-associated hyperviscosity. Transfusion. 2021; 61(4): 1029-1034.
     Google Scholar
  20. Gucyetmez B, Atalan HK, Sertdemir I, Cakir U, Telci L. Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: a retrospective study. Critical Care. 2020; 24: 1-4.
     Google Scholar
  21. Patidar GK, Land KJ, Vrielink H, Rahimi-Levene N, Dann EJ, Al-Humaidan H, et al. Understanding the role of therapeutic plasma exchange in COVID-19: preliminary guidance and practices. Vox Sang. 2021; 116(7): 798-807.
     Google Scholar
  22. Gilcher RO, Smith JW. Apheresis: Principles and technology of hemapheresis. Rossi's Principles of Transfusion Medicine. 2009.
     Google Scholar
  23. Assessment of plasmapheresis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 1996; 47: 840 –43.
     Google Scholar
  24. Joan C, Gloria C, Bienvenida A, Antonio B, Ana GC, Miguel L. Efficacy and safety of plasma exchange: an 11-year single-center experience of 2730 procedures in 317 patients. Transfusion and Apheresis Science. 2014; (51): 209-214.
     Google Scholar
  25. Pene F, Vigneau C, Auburtin M, Moreau D, Zahar JR, Coste J, et al. Outcome of severe adult thrombotic microangiopathies in the intensive care unit. Intensive Care Medicine. 2005; 31(1): 71-78.
     Google Scholar
  26. Darmon M, Azoulay E, Thiery G, Ciroldi M, Galicier L, Parquet N, et al. Time course of organ dysfunction in thrombotic microangiopathy patients receiving either plasma perfusion or plasma exchange. Critical Care Medicine. 2006; 34(8): 2127-33.
     Google Scholar
  27. Carrillo IG, Demelo-Rodriguez P, Ferrero ML, Anaya F. Double filtration plasmapheresis in the treatment of pancreatitis due to severe Hypertriglyceridemia. Journal of Clinical Lipidology. 2015; 9(5): 698-702.
     Google Scholar
  28. Kyriakidis AV, Raitsiou B, Sakagianni A, Harisopoulou V, Pyrgioti M, Panagopoulou A, et al. Management of acute severe hyperlipidemic pancreatitis. Digestion. 2006; 73(4): 259-64.
     Google Scholar
  29. Syed H, Bilusic M, Rhondla C, Tavaria A. Plasmapheresis in the treatment of hypertriglyceridemia-induced pancreatitis: A community hospital's experience. J Clin Apher. 2010; 25(4): 229-34.
     Google Scholar
  30. Chang CT, Tsai TY, Liao HY, Chang CM, Jheng JS, Huang WH, et al. Double filtration plasma apheresis shortens hospital admission duration of patients with severe hypertriglyceridemia-associated acute pancreatitis. Pancreas. 2016; 45(4): 606-12.
     Google Scholar
  31. Aguirre-Valencia D, Naranjo-Escobar J, Posso-Osorio I, Macía-Mejía MC, Nieto-Aristizábal I, Barrera T, et al. Therapeutic Plasma Exchange as Management of Complicated Systemic Lupus Erythematosus and Other Autoimmune Diseases. Autoimmune Dis. 2019; 2019: 5350960.
     Google Scholar
  32. Pons-Estel GJ, Salerni GE, Serrano RM, Gomez-Puerta JA, Plasin MA, Aldasoro E, et al. Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature. Autoimmunity Reviews. 2011; 10(11): 679-84.
     Google Scholar
  33. Kim M, Martin ST, Townsend KR, Gabardi S. Antibody‐mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2014; 34(7): 733-44.
     Google Scholar
  34. Gubensek J, Buturovic-Ponikvar J, Kandus A, Arnol M, Kovac J, Marn-Pernat A, et al. Plasma exchange and intravenous immunoglobulin in the treatment of antibody-mediated rejection after kidney transplantation: a single-center historic cohort study. Transplant Proc. 2013; 45(4): 1524-7.
     Google Scholar
  35. Gubensek J, Buturovic‐Ponikvar J, Kandus A, Arnol M, Lindic J, Kovac D, et al. Treatment of Antibody‐Mediated Rejection After Kidney Transplantation–10 Years' Experience With Apheresis at a Single Center. Therapeutic Apheresis and Dialysis. 2016; 20(3): 240-5.
     Google Scholar
  36. Brown CM, Abraham KA, O'Kelly P, Conlon PJ, Walshe JJ. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation. Transplant Proc. 2009; 41(9): 3690-2.
     Google Scholar
  37. Cravedi P, Kopp JB, Remuzzi G. Recent progress in the pathophysiology and treatment of FSGS recurrence. American Journal of Transplantation. 2013; 13(2): 266-74.
     Google Scholar
  38. Ponticelli C, Glassock RJ. Posttransplant recurrence of primary glomerulonephritis. Clinical Journal of the American Society of Nephrology. 2010; 5(12): 2363-72.
     Google Scholar
  39. Kashgary A, Sontrop JM, Li L, Al-Jaishi AA, Habibullah ZN, Alsolaimani R, et al. The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: A systematic review and meta-analysis of 77 case-reports and case-series. BMC Nephrol. 2016; 17(1): 104.
     Google Scholar
  40. McLeod BC. Therapeutic apheresis: use of human serum albumin, fresh frozen plasma and cryosupernatant plasma in therapeutic plasma exchange. Best Pract Res Clin Haematol. 2006; 19(1): 157-67.
     Google Scholar
  41. Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher. 2007; 22(5): 270-6.
     Google Scholar